Aripiprazole
Find comprehensive information on Aripiprazole (Abilify, Aristada, Abilify Maintena) for accurate clinical documentation and medical coding. Learn about Aripiprazole diagnosis, administration, and potential adverse effects. This resource supports healthcare professionals in proper coding and documentation practices related to Aripiprazole treatment, ensuring compliance and optimized patient care. Explore details on Abilify, Aristada, and Abilify Maintena for precise clinical records.
Atypical antipsychotic used to treat schizophrenia, bipolar disorder, and major depressive disorder.
Hallucinations, delusions, mania, depression, irritability, mood swings.
Outpatient psychiatry, inpatient psychiatric units, community mental health centers.
ICD-10 Code Families
Complete code families applicable to Z79.899
When to use each related code
| Description | When to use |
|---|---|
| Atypical antipsychotic for schizophrenia, bipolar disorder, and depression. | Consider for schizophrenia, bipolar mania/mixed episodes, major depressive disorder adjunct, irritability associated with autism. |
| Atypical antipsychotic similar to aripiprazole, for schizophrenia and bipolar disorder. | Use for acute and maintenance treatment of schizophrenia and bipolar I disorder (mania and mixed episodes). |
| Antipsychotic often used for schizophrenia and bipolar disorder when other treatments fail. | Reserve for treatment-resistant schizophrenia and bipolar disorder due to higher risk of side effects. |
Best-practice checklist
- ✓Aripiprazole (Abilify) diagnosis: ICD-10 code, documented indication
- ✓Aripiprazole dosage, frequency, route documented
- ✓Patient response to Aripiprazole therapy noted
- ✓Prior authorization for Abilify Maintena if applicable
- ✓Aripiprazole side effects documented in patient chart
Common pitfalls to avoid
Coding for unapproved indications like anxiety or insomnia without proper documentation creates compliance and billing risks.
Incorrect coding for oral (Abilify) vs. injectable (Aristada, Abilify Maintena) can lead to claim denials and revenue loss.
Failure to accurately code co-existing conditions like schizophrenia or bipolar disorder with aripiprazole impacts reimbursement and quality metrics.
Best-practice tips
- 01Document aripiprazole indication (ICD-10-CM) for medical necessity.
- 02Query prescriber to specify Abilify, Aristada, or Maintena (NDC) for billing accuracy.
- 03Monitor and document akathisia, insomnia for improved patient care and risk adjustment.
- 04Ensure aripiprazole dosage aligns with FDA guidelines and payer policies for compliance.
- 05Educate patients on adherence, potential adverse effects for optimized outcomes and safety.
Step-by-step checklist
- 1
Verify diagnosis supporting aripiprazole use (ICD-10 F20-F39, F60.3, F90.x)
- 2
Confirm no contraindications: hypersensitivity, dementia-related psychosis
- 3
Check baseline EKG, especially QTc interval, document in chart
- 4
Monitor for adverse effects: akathisia, weight gain, metabolic changes
- 5
Document informed consent discussing benefits, risks of aripiprazole therapy
Ready-to-paste narrative
Patient presents for follow-up management of schizophrenia, diagnosed via DSM-5 criteria. The patient reports continued improvement in positive symptoms such as auditory hallucinations and delusional thinking since initiating aripiprazole therapy. Current medication regimen includes aripiprazole (Abilify Maintena) administered intramuscularly monthly. Patient denies any current suicidal or homicidal ideation. Mental status examination reveals clear speech, organized thought processes, and appropriate affect. Patient reports mild akathisia, managed with propranolol. No other extrapyramidal symptoms or adverse effects noted. Assessment: Schizophrenia, stable on current aripiprazole treatment. Plan: Continue aripiprazole Maintena at current dosage. Monitor for efficacy and tolerability, including akathisia, and adjust propranolol as needed. Patient education provided regarding medication adherence, potential side effects, and importance of follow-up appointments. ICD-10 code F20.9 (Schizophrenia, unspecified) and CPT code 90837 (Individual psychotherapy) applied for this session. Next appointment scheduled in four weeks to coincide with next injection. Discussed medication management, including the benefits of long-acting injectable aripiprazole (Aristada, Abilify Maintena) for improved adherence and relapse prevention. Emphasis placed on the importance of shared decision-making in antipsychotic selection and dosage adjustment.
Common questions and answers
What are the most effective strategies for managing aripiprazole weight gain in patients with schizophrenia, considering both pharmacological and non-pharmacological interventions?+
Aripiprazole, while effective for schizophrenia, can lead to weight gain, a significant concern for long-term management. Strategies for mitigating this include careful monitoring of weight and metabolic parameters, dietary counseling emphasizing a balanced, calorie-controlled diet, and encouraging regular physical activity. Pharmacologically, switching to a lower dose or a different antipsychotic with a lower propensity for weight gain, such as ziprasidone or lurasidone, can be considered. Metformin has shown some promise as an adjunctive treatment in mitigating aripiprazole-induced weight gain. However, any changes should be made in consultation with the patient and after careful consideration of their overall clinical picture. Explore how a multidisciplinary approach involving psychiatrists, dieticians, and exercise specialists can optimize patient outcomes. Consider implementing a standardized protocol for weight monitoring and intervention in your practice.
How do I differentiate akathisia caused by aripiprazole from the restlessness sometimes seen in schizophrenia itself, and what are the best management approaches?+
Differentiating aripiprazole-induced akathisia from the intrinsic restlessness of schizophrenia can be challenging. Akathisia typically presents as subjective inner restlessness and an inability to sit still, accompanied by objective signs like pacing, rocking, or foot-tapping. In contrast, the restlessness in schizophrenia is often more disorganized and less clearly defined. Careful history taking, including the timing of symptom onset in relation to aripiprazole initiation or dose adjustment, is crucial. Consider using standardized rating scales like the Barnes Akathisia Rating Scale (BARS) to assess the severity of akathisia. Management strategies include reducing the aripiprazole dose or switching to a different antipsychotic. Beta-blockers, such as propranolol, or anticholinergic medications, like benztropine, can be used for symptomatic relief. Learn more about the specific benefits and risks associated with each intervention to tailor your approach to individual patient needs.
When transitioning a patient with schizophrenia from oral aripiprazole to a long-acting injectable formulation like Abilify Maintena or Aristada, what key considerations should clinicians keep in mind to ensure a smooth transition and maintain treatment adherence?+
Transitioning to long-acting injectable aripiprazole (LAI) offers benefits for patients with schizophrenia who struggle with adherence to oral medication. Key considerations for a smooth transition include ensuring the patient understands the benefits and risks of LAIs, addressing any concerns or misconceptions they may have, and establishing a clear injection schedule. During the initial overlap period, where both oral and LAI aripiprazole are administered, close monitoring for potential adverse events is essential. The specific overlap duration depends on the chosen LAI formulation (Abilify Maintena or Aristada) and individual patient factors. Clear communication with the patient and their support system is crucial throughout the transition process. Explore how patient education materials and shared decision-making can enhance adherence and improve long-term outcomes. Consider implementing a follow-up plan to monitor medication effectiveness and address any emerging issues.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.